Starting your Wegovy 3rd dose: what changes at 1mg

Eight weeks in: the moment your prescription changes

Picture this: you have finished your second box of Wegovy pens, your pen-change date is circled on the phone calendar, and a fresh 1mg box is sitting in the fridge. This is where most people pause and ask whether they should feel different, whether nausea will come back, and whether the 1mg dose will finally shift the scale.

The Wegovy schedule follows a fixed titration path: 0.25mg for four weeks, then 0.5mg for four weeks, then 1mg. Semaglutide works by acting on GLP-1 receptors in the brain and gut, reducing appetite signals and slowing how quickly the stomach empties. At 1mg, the receptor activation is meaningfully higher than at 0.5mg, which is why many people notice a clearer reduction in hunger from around the second week at this dose. The NHS medicines information for semaglutide sets out the full titration pathway and what to do if you miss a dose or need to stay longer at a given step.

One thing worth saying plainly: the 1mg dose is a therapeutic step in its own right, not just a bridge to the higher doses. Some people stay here for longer than four weeks if their prescriber judges it sensible based on tolerability. Your experience at 1mg informs every decision after it.

The side effects that catch people out at the third step

A common misconception is that once you tolerate 0.5mg well, the jump to 1mg will feel identical. It often does not, at least for the first week or two. The dose increase shifts how the medicine interacts with your digestive system, and nausea, loose stools or indigestion can return briefly before settling. This is not a sign something has gone wrong; it is the same adjustment process you went through at the very start, compressed into a shorter window because your system already has some familiarity with the medicine.

Practical steps that help most people: eat smaller portions than you think you need, avoid high-fat and heavily spiced meals in the first fortnight at the new dose, and keep fluids up. If vomiting is severe or persists beyond a few days, that is a conversation for your prescriber, not something to sit through. The MHRA Yellow Card scheme also allows you to report any side effects directly to the regulator, which contributes to ongoing safety monitoring for semaglutide.

Injection technique matters more than people realise at this stage. Rotating between the abdomen, thigh and upper arm, and allowing the pen to reach room temperature before injecting, both reduce injection-site discomfort. If you are ever unsure whether you are using your device correctly, our guide to how the Wegovy pen dose works walks through the process in detail. Your patient information leaflet covers the exact steps.

How appetite and weight loss typically shift at 1mg

For many people, the 1mg dose is the first point where appetite suppression feels genuinely significant day to day, not just a slight reduction. Portion sizes that previously felt manageable start feeling like more than enough. The urge to snack between meals often drops. This is the GLP-1 mechanism working at a higher level of engagement. Clinical trial data for semaglutide at the full 2.4mg maintenance dose showed an average body weight reduction of around 15% over 68 weeks, the 1mg step is where meaningful progress toward that trajectory often begins, though individual responses vary considerably.

It is also the point where people sometimes panic that they are not losing fast enough. Progress at this stage is real even when the scale is slow. Body composition, energy levels and reduced hunger are all relevant markers. If you want to understand how the full Wegovy dose ladder works from start to maintenance, our overview covers each step in context. For a closer look at where you are right now, our page on the Wegovy dose at this stage of treatment explains what to expect and how each step builds on the last.

Weight loss at any stage of treatment is a clinical journey, not a fixed schedule. Cost is sometimes a factor in deciding whether to continue, and our page on Wegovy pricing in the UK explains what private treatment typically includes and how to read a price clearly.

What your prescriber is watching for before you move on

Moving from the 1mg pen to the next dose (1.7mg) is not automatic. Your prescriber reviews how you have tolerated the current dose, whether your weight trend is consistent, and whether there are any clinical reasons to pause. Understanding what the Wegovy 0.5mg dose involves and how it prepares you for the steps that follow can also help you make sense of your progress so far. At nume, that review happens before every repeat order, a qualified prescriber reads your update, not a checklist run by software. Our approach to clinical oversight is built around that individual review at every stage.

If you are transferring to nume from another provider while already on the 1mg dose, you will be asked to provide evidence of your current treatment before any dose is confirmed. This protects you: dose increases should reflect your actual clinical history, not an assumption. You can read about Wegovy as a treatment in full, including how the NHS and private routes differ, or explore weight management treatment options more broadly if you are still deciding. When you are ready to take the next step, start a free consultation with our prescribers.